The Food and Drug Administration granted priority review to Exelixis Inc. (Nasdaq: EXEL) for its Cabometyx to treat advanced renal cell carcinoma. Shares of the biopharmaceutical leaped $4.26 to close at $29.02.
Priority review granted to Exelixis
October 16, 2017 at 17:46 PM EDT
